Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study
Go back to Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.82 | 52 Week High | $77.12 | |||
| Open | $66.82 | 52 Week Low | $49.03 | |||
| Day High | $66.82 | P/E | 43.39 | |||
| Day Low | $66.82 | EPS | $1.54 | |||
| Volume | 1,003 | |||||
